ESR1 and breast carcinoma: We divided the data into a training set (n = 130) and a validation set (n = 100) and developed a series of classifiers to predict (a) ER status, (b) pathologic complete response (pCR) to preoperative chemotherapy for all breast cancers, and (c) pCR for ER-negative breast cancers.